Supernus Pharmaceuticals (SUPN) Competitors $46.13 +1.33 (+2.97%) Closing price 04:00 PM EasternExtended Trading$45.54 -0.59 (-1.28%) As of 06:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SUPN vs. JAZZ, CORT, PRGO, PCRX, NKTR, OMER, ASMB, CPIX, LLY, and JNJShould you be buying Supernus Pharmaceuticals stock or one of its competitors? The main competitors of Supernus Pharmaceuticals include Jazz Pharmaceuticals (JAZZ), Corcept Therapeutics (CORT), Perrigo (PRGO), Pacira BioSciences (PCRX), Nektar Therapeutics (NKTR), Omeros (OMER), Assembly Biosciences (ASMB), Cumberland Pharmaceuticals (CPIX), Eli Lilly and Company (LLY), and Johnson & Johnson (JNJ). These companies are all part of the "pharmaceuticals" industry. Supernus Pharmaceuticals vs. Its Competitors Jazz Pharmaceuticals Corcept Therapeutics Perrigo Pacira BioSciences Nektar Therapeutics Omeros Assembly Biosciences Cumberland Pharmaceuticals Eli Lilly and Company Johnson & Johnson Supernus Pharmaceuticals (NASDAQ:SUPN) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, risk, media sentiment, earnings and institutional ownership. Do analysts rate SUPN or JAZZ? Supernus Pharmaceuticals currently has a consensus price target of $43.00, indicating a potential downside of 6.79%. Jazz Pharmaceuticals has a consensus price target of $178.67, indicating a potential upside of 36.19%. Given Jazz Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Jazz Pharmaceuticals is more favorable than Supernus Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Supernus Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50Jazz Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 14 Buy rating(s) 0 Strong Buy rating(s) 2.88 Is SUPN or JAZZ more profitable? Supernus Pharmaceuticals has a net margin of 9.70% compared to Jazz Pharmaceuticals' net margin of -9.91%. Supernus Pharmaceuticals' return on equity of 14.22% beat Jazz Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Supernus Pharmaceuticals9.70% 14.22% 10.82% Jazz Pharmaceuticals -9.91%5.02%1.73% Does the media prefer SUPN or JAZZ? In the previous week, Jazz Pharmaceuticals had 12 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 20 mentions for Jazz Pharmaceuticals and 8 mentions for Supernus Pharmaceuticals. Jazz Pharmaceuticals' average media sentiment score of 1.34 beat Supernus Pharmaceuticals' score of 0.91 indicating that Jazz Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Supernus Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Jazz Pharmaceuticals 16 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger earnings and valuation, SUPN or JAZZ? Jazz Pharmaceuticals has higher revenue and earnings than Supernus Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Supernus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSupernus Pharmaceuticals$661.82M3.91$73.86M$1.1540.11Jazz Pharmaceuticals$4.07B1.96$560.12M-$6.73-19.49 Which has more risk & volatility, SUPN or JAZZ? Supernus Pharmaceuticals has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500. Comparatively, Jazz Pharmaceuticals has a beta of 0.24, indicating that its stock price is 76% less volatile than the S&P 500. Do insiders & institutionals have more ownership in SUPN or JAZZ? 89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. 8.8% of Supernus Pharmaceuticals shares are owned by insiders. Comparatively, 4.3% of Jazz Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummarySupernus Pharmaceuticals and Jazz Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks. Get Supernus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SUPN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SUPN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SUPN vs. The Competition Export to ExcelMetricSupernus PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.51B$4.26B$5.76B$10.29BDividend YieldN/A1.33%5.74%4.60%P/E Ratio40.1111.0576.8626.96Price / Sales3.9115.77539.94127.44Price / Cash10.747.0437.1760.63Price / Book2.463.3013.836.37Net Income$73.86M-$134.23M$3.29B$271.46M7 Day Performance-1.14%-2.30%0.93%2.35%1 Month Performance7.30%4.09%5.31%7.78%1 Year Performance44.88%36.10%84.25%32.27% Supernus Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SUPNSupernus Pharmaceuticals2.7979 of 5 stars$46.13+3.0%$43.00-6.8%+41.2%$2.51B$661.82M40.11580Positive NewsInsider TradeJAZZJazz Pharmaceuticals4.5458 of 5 stars$129.85+0.3%$178.67+37.6%+16.1%$7.86B$4.07B-19.292,800Positive NewsCORTCorcept Therapeutics4.7615 of 5 stars$71.23+2.7%$134.50+88.8%+89.3%$7.31B$675.04M63.04300Positive NewsPRGOPerrigo4.8918 of 5 stars$22.31-1.5%$33.00+47.9%-24.6%$3.12B$4.37B-38.468,379Positive NewsPCRXPacira BioSciences3.3647 of 5 stars$26.74+1.1%$30.83+15.3%+81.7%$1.19B$700.97M-9.62720Positive NewsNKTRNektar Therapeutics4.1611 of 5 stars$44.33+10.3%$88.33+99.3%+161.9%$764.17M$98.43M-5.04220News CoverageGap UpHigh Trading VolumeOMEROmeros3.6212 of 5 stars$4.21+1.0%$18.00+327.6%+1.5%$283.79MN/A-2.00210ASMBAssembly Biosciences3.1978 of 5 stars$23.32-2.1%$41.33+77.2%+13.4%$182.71M$28.52M-4.18100Short Interest ↑CPIXCumberland Pharmaceuticals0.3359 of 5 stars$3.31flatN/A+152.3%$49.52M$42.07M-15.0580LLYEli Lilly and Company4.9965 of 5 stars$738.58+1.6%$950.17+28.6%-16.1%$688.27B$53.26B48.2747,000Trending NewsAnalyst ForecastJNJJohnson & Johnson4.7361 of 5 stars$178.30-0.1%$176.29-1.1%+5.9%$429.72B$90.63B19.07138,100Trending NewsAnalyst Forecast Related Companies and Tools Related Companies JAZZ Alternatives CORT Alternatives PRGO Alternatives PCRX Alternatives NKTR Alternatives OMER Alternatives ASMB Alternatives CPIX Alternatives LLY Alternatives JNJ Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SUPN) was last updated on 9/18/2025 by MarketBeat.com Staff From Our PartnersRecession Risk: 90% — Are Your Savings Ready?Moody's latest report shows one-third of U.S. economic activity is already in recession or at high risk.Lear Capital | SponsoredREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Supernus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Supernus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SUPN Stock Alerts